Supplemental Online Content

Azar I, Yazdanpanah O, Jang H, et al. Comparison of carboplatin with cisplatin in small cell lung cancer in US veterans. *JAMA Netw Open*. 2022;5(10):e2237699. doi:10.1001/jamanetworkopen.2022.37699

eTable 1. Baseline Characteristics of ES-SCLC
eTable 2. Baseline Characteristics of LS-SCLC

This supplemental material has been provided by the authors to give readers additional information about their work.
**eTable 1. Baseline Characteristics of ES-SCLC**

|                      | All (n=2652)* | Carboplatin (n=2032) | Cisplatin (n=660) | P value* |
|----------------------|---------------|----------------------|-------------------|----------|
| **Gender – no. (%)** |               |                      |                   | 0.008    |
| Female               | 69 (2.6%)     | 45 (2.2%)            | 28 (4.2%)         |          |
| Male                 | 2583 (97.4%)  | 1987 (97.8%)         | 632 (95.8%)       |          |
| **Age – no. (%)**    |               |                      |                   | <0.001   |
| 40-49 years          | 13 (0.5%)     | 3 (0.1%)             | 10 (1.5%)         |          |
| 50-59 years          | 371 (14.0%)   | 238 (11.7%)          | 142 (21.5%)       |          |
| 60-69 years          | 1327 (50.0%)  | 981 (48.3%)          | 368 (55.8%)       |          |
| ≥70 years            | 941 (35.5%)   | 810 (39.9%)          | 140 (21.2%)       |          |
| **Race – no. (%)**   |               |                      |                   | 0.82     |
| African American     | 239 (9.0%)    | 183 (9.0%)           | 62 (9.4%)         |          |
| White                | 2187 (82.5%)  | 1684 (82.9%)         | 534 (80.9%)       |          |
| Other∥               | 49 (1.8%)     | 38 (1.9%)            | 11 (1.7%)         |          |
| Declined to          | 177 (6.7%)    | 127 (6.2%)           | 53 (8%)           |          |
| Answer/Unknown       |               |                      |                   |          |
| **Ethnicity – no. (%)** |         |                      |                   | 0.22     |
| Hispanic or Latino   | 39 (1.5%)     | 26 (1.3%)            | 13 (2.0%)         |          |
| Not Hispanic or Latino | 2489 (93.9%) | 1919 (94.4%)        | 609 (92.3%)       |          |
| Performance status – no. (%) | Count (Percentage) | Count (Percentage) | Count (Percentage) |
|-------------------------------|--------------------|--------------------|--------------------|
| Declined to Answer/Unknown    | 124 (4.7%)         | 87 (4.3%)          | 38 (5.8%)          |
| ECOG 0                        | 285 (10.7%)        | 212 (10.4%)        | 76 (11.5%)         |
| ECOG 1                        | 709 (26.7%)        | 560 (27.6%)        | 160 (24.2%)        |
| ECOG 2                        | 373 (14.1%)        | 293 (14.4%)        | 87 (13.2%)         |
| ECOG 3                        | 150 (5.7%)         | 127 (6.2%)         | 28 (4.2%)          |
| ECOG 4                        | 11 (0.4%)          | 9 (0.4%)           | 2 (0.3%)           |
| ECOG 5                        | 4 (0.2%)           | 3 (0.1%)           | 1 (0.2%)           |
| Unknown                       | 1120 (42.2%)       | 828 (40.7%)        | 306 (46.4%)        |

* 40 patients received both carboplatin and cisplatin;

# Fisher’s exact test

Asian, American Indian or Alaskan Native, Native Hawaiian or other Pacific Islander, and multiple race
### eTable 2. Baseline Characteristics of LS-SCLC

|                      | All (n=1756)* | Carboplatin (n=801) | Cisplatin (n=1018) | P value# |
|----------------------|--------------|---------------------|-------------------|---------|
| **Gender – no. (%)** |              |                     |                   |         |
| Female               | 87 (5.0%)    | 39 (4.9%)           | 52 (5.1%)         | 0.83    |
| Male                 | 1669 (95.0%) | 762 (95.1%)         | 966 (94.9%)       |         |
| **Age – no. (%)**    |              |                     |                   | <0.001  |
| 30-39 years          | 2 (0.1%)     | 0 (0%)              | 2 (0.2%)          |         |
| 40-49 years          | 24 (1.4%)    | 7 (0.9%)            | 19 (1.9%)         |         |
| 50-59 years          | 260 (14.8%)  | 85 (10.6%)          | 188 (18.5%)       |         |
| 60-69 years          | 935 (53.2%)  | 380 (47.4%)         | 589 (57.9%)       |         |
| ≥70 years            | 535 (30.5%)  | 329 (41.1%)         | 220 (21.6%)       |         |
| **Race – no. (%)**   |              |                     |                   | 0.42    |
| African American     | 212 (12.1%)  | 95 (11.9%)          | 125 (12.3%)       |         |
| White                | 1402 (79.8%) | 651 (81.3%)         | 800 (78.6%)       |         |
| Other\(^k\)          | 28 (1.6%)    | 10 (1.2%)           | 18 (1.8%)         |         |
| Declined to Answer/Unknown | 114 (6.5%) | 45 (5.6%)           | 75 (7.4%)         |         |
| **Ethnicity – no. (%)** |            |                     |                   | 0.16    |
| Hispanic or Latino   | 30 (1.7%)    | 8 (1.0%)            | 22 (2.2%)         |         |
| Not Hispanic or Latino | 1653 (94.1%) | 759 (94.8%)        | 953 (93.6%)       |         |
| Declined to Answer/Unknown | 73 (4.2%) | 34 (4.2%)           | 43 (4.2%)         |         |

© 2022 Azar I et al. *JAMA Network Open.*
| Performance status – no. (%) |       |       |       |
|-----------------------------|-------|-------|-------|
| ECOG 0                      | 344 (19.6%) | 150 (18.7%) | 207 (20.3%) |
| ECOG 1                      | 559 (31.8%) | 258 (32.2%) | 323 (31.7%) |
| ECOG 2                      | 146 (8.3%) | 82 (10.2%) | 70 (6.9%) |
| ECOG 3                      | 38 (2.2%) | 27 (3.4%) | 12 (1.2%) |
| ECOG 4                      | 3 (0.2%) | 2 (0.2%) | 1 (0.1%) |
| Unknown                     | 666 (37.9%) | 282 (35.2%) | 405 (39.8%) |

* 63 patients received both carboplatin and cisplatin

# Fisher’s exact test

‡ Asian, American Indian or Alaskan Native, and Native Hawaiian or other Pacific Islander